Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 137Skin Neoplasms 21Neoplasm Metastasis 19Carcinoma, Renal Cell 16Kidney Neoplasms 15Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasms 3Urinary Bladder Neoplasms 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Melanoma, Experimental 2Lymphoma, Non-Hodgkin 2

Interventions

Cyclophosphamide 7fludarabine 4pembrolizumab 2fludarabine phosphate 1aldesleukin 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Mass Spectrometry 1Leukapheresis 1Interleukin-2 1Injections 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Drug Therapy 1Decitabine 1Chromatography, High Pressure Liquid 1Biological Therapy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × aldesleukin × Dermatologic × Clear all
NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡